Advances in the Treatment of Non-Small Cell Lung Cancer: Immunotherapy.
Clin Chest Med
; 41(2): 237-247, 2020 06.
Article
en En
| MEDLINE
| ID: mdl-32402359
ABSTRACT
Clinical development of immune checkpoint blockade has dramatically changed the treatment paradigm and prognosis for patients with non-small cell lung cancer. Immune checkpoint blockade with PD-1 and PD-L1 antibodies generates clinically significant, durable responses in patients with advanced non-small cell lung cancer. These agents are approved for first- and second-line treatment, either as single agents or in combination with chemotherapy and angiogenesis inhibitors. Although the toxicity profile of these treatments is favorable, a unique set of immune-mediated adverse events, such as pneumonitis, has been observed. Broader use of these agents is improving survival for patients with advanced lung cancer.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Carcinoma de Pulmón de Células no Pequeñas
/
Inmunoterapia
/
Neoplasias Pulmonares
Límite:
Humans
Idioma:
En
Revista:
Clin Chest Med
Año:
2020
Tipo del documento:
Article